Dr. Elena Provenzano Unveils the Future of AI in HER2 Low Interpretation at USCAP 2024

Back

Dr. Elena Provenzano from Cambridge University Hospitals delivered a compelling presentation at USCAP 2024, highlighting advancements in HER2 assessment in breast cancer. Her talk explored the nuances of HER2 testing methodologies, drawing from pivotal studies like the Destiny trial. As a leading figure in digital pathology, Dr. Provenzano emphasized the integration of AI in enhancing diagnostic precision, offering insights into its transformative potential for breast cancer care.

Back

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our AI platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our AI platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.

How is artificial intelligence rising to the challenge in breast cancer diagnosis?

How ‘game-changing’ AI is helping discover cancer for the first time in UK | ITV News

The AI revolution in cancer diagnostics with Joseph Mossel, CEO of Ibex Medical Analytics